drugset / Trial / NCT00664430
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the efficacy and safety of paricalcitol in participants with moderate to severe secondary hyperparathyroidism (SHPT) undergoing hemodialysis who are resistant to treatment with calcitriol.
Timeline
- Start
- 2009-01
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Calcitriol | Small molecule | — | — |
| Subject | Paricalcitol | Other / unclassified | 0.04 ug/kg | — |
| Subject | Paricalcitol | Other / unclassified | 0.1 ug/kg | — |